TVB-2640 is primarily investigated for its potential in treating various types of cancer. It functions as a FASN (fatty acid synthase) inhibitor, which plays a crucial role in lipid metabolism, a process often dysregulated in cancer cells. By inhibiting FASN, TVB-2640 aims to disrupt the lipid synthesis pathway, thereby starving cancer cells of the essential lipids they need for growth and survival. This mechanism is particularly promising in cancers that are heavily dependent on lipid metabolism, such as breast, ovarian, and colorectal cancers. Additionally, TVB-2640 is being explored for its potential in non-alcoholic steatohepatitis (NASH), a liver condition characterized by fat accumulation, inflammation, and fibrosis. By targeting FASN, it may help reduce liver fat and inflammation, offering a therapeutic option for patients with NASH. Clinical trials are ongoing to further evaluate its efficacy and safety in these applications.